PubMed=8086765; DOI=10.1007/BF00252823
Gross A.J., Wolff M., Fandrey J., Miersch W.-D.E., Dieckmann K.-P., Jelkmann W.
Prevalence of paraneoplastic erythropoietin production by renal cell carcinomas.
Clin. Investig. 72:337-340(1994)

PubMed=10190320; DOI=10.1007/s004320050252
Frank M.H., Pomer S.
Interferon alpha2b differentially affects proliferation of two human renal cell carcinoma cell lines differing in the P-glycoprotein-associated multidrug-resistant phenotype.
J. Cancer Res. Clin. Oncol. 125:117-120(1999)

PubMed=15977034; DOI=10.1007/s10334-005-0107-7
Lutz N.W., Franks S.E., Frank M.H., Pomer S., Hull W.E.
Investigation of multidrug resistance in cultured human renal cell carcinoma cells by 31P-NMR spectroscopy and treatment survival assays.
MAGMA 18:144-161(2005)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)